Compare HALO & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HALO | SNEX |
|---|---|---|
| Founded | 1998 | 1924 |
| Country | United States | United States |
| Employees | N/A | 5400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.1B |
| IPO Year | 2001 | 1996 |
| Metric | HALO | SNEX |
|---|---|---|
| Price | $78.05 | $106.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $78.64 | ★ $81.33 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.22 | ★ 3.74 |
| Revenue | $151,862,000.00 | ★ $132,378,200,000.00 |
| Revenue This Year | $28.24 | N/A |
| Revenue Next Year | $12.56 | $4.17 |
| P/E Ratio | $63.51 | ★ $29.66 |
| Revenue Growth | N/A | ★ 32.53 |
| 52 Week Low | $55.64 | $68.97 |
| 52 Week High | $82.26 | $141.99 |
| Indicator | HALO | SNEX |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 35.81 |
| Support Level | $67.12 | $105.27 |
| Resistance Level | $82.24 | $129.45 |
| Average True Range (ATR) | 2.46 | 6.53 |
| MACD | -0.33 | -2.26 |
| Stochastic Oscillator | 46.95 | 5.07 |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.